Trial Profile
A Randomized, Single-blind, Placebo-controlled, Sequential Parallel-Group and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KBP-7072 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Zifanocycline (Primary)
- Indications Bacterial infections
- Focus Adverse reactions
- Sponsors KBP Biosciences
- 08 Oct 2017 Results assessing safety, tolerability and pharmacokinetics of KBP-7072, presented at the IDWeek 2017.
- 13 May 2016 Status changed from recruiting to completed.
- 28 Jan 2016 New trial record